BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol 2013;34:90-8. [PMID: 23031830 DOI: 10.1016/j.it.2012.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Chan WM, McFadden G. Oncolytic Poxviruses. Annu Rev Virol 2014;1:119-41. [PMID: 25839047 DOI: 10.1146/annurev-virology-031413-085442] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 6.5] [Reference Citation Analysis]
2 Bai Y, Hui P, Du X, Su X. Updates to the antitumor mechanism of oncolytic virus.Thorac Cancer. 2019;10:1031-1035. [PMID: 30900824 DOI: 10.1111/1759-7714.13043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
3 Wages NA, Slingluff CL Jr, Bullock TN, Petroni GR. Tailoring early-phase clinical trial design to address multiple research objectives. Cancer Immunol Immunother 2020;69:95-102. [PMID: 31807879 DOI: 10.1007/s00262-019-02442-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Nazarian AA, Archibeque IL, Nguyen YH, Wang P, Sinclair AM, Powers DA. Characterization of bispecific T-cell Engager (BiTE) antibodies with a high-capacity T-cell dependent cellular cytotoxicity (TDCC) assay. J Biomol Screen 2015;20:519-27. [PMID: 25477202 DOI: 10.1177/1087057114561405] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
5 Burdach S, Kolb HJ. The vigor of defense against non-self: potential superiority of allorestricted T cells in immunotherapy of cancer? Front Oncol 2013;3:100. [PMID: 23653891 DOI: 10.3389/fonc.2013.00100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
6 Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. Clin Transl Sci. 2016;9:89-104. [PMID: 26924066 DOI: 10.1111/cts.12391] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 17.3] [Reference Citation Analysis]
7 Guncheva M, Paunova K, Ossowicz P, Rozwadowski Z, Janus E, Idakieva K, Todinova S, Raynova Y, Uzunova V, Apostolova S, Tzoneva R, Yancheva D. Rapana thomasiana hemocyanin modified with ionic liquids with enhanced anti breast cancer activity. Int J Biol Macromol 2016;82:798-805. [PMID: 26478091 DOI: 10.1016/j.ijbiomac.2015.10.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
8 Zhou X, Mo X, Qiu J, Zhao J, Wang S, Zhou C, Su Y, Lin Z, Ma H. Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis. Cancer Manag Res 2018;10:5363-72. [PMID: 30464632 DOI: 10.2147/CMAR.S173201] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Kim M, Pyo S, Kang CH, Lee CO, Lee HK, Choi SU, Park CH. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS One 2018;13:e0198347. [PMID: 29874279 DOI: 10.1371/journal.pone.0198347] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
10 Zhen YH, Liu XH, Yang Y, Li B, Tang JL, Zeng QX, Hu J, Zeng XN, Zhang L, Wang ZJ, Li XY, Ge HX, Winqvist O, Hu PS, Xiu J. Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. Cancer Immunol Immunother. 2015;64:1083-1093. [PMID: 25990075 DOI: 10.1007/s00262-015-1715-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
11 De Wolf K, Vermaelen K, De Meerleer G, Lambrecht BN, Ost P. The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology 2015;4:e1042198. [PMID: 26464810 DOI: 10.1080/2162402X.2015.1042198] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
12 Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Current Opinion in Chemical Biology 2013;17:385-92. [DOI: 10.1016/j.cbpa.2013.03.029] [Cited by in Crossref: 121] [Cited by in F6Publishing: 102] [Article Influence: 13.4] [Reference Citation Analysis]
13 Wheat W, Chow L, Coy J, Contreras E, Lappin M, Dow S. Activation of upper respiratory tract mucosal innate immune responses in cats by liposomal toll-like receptor ligand complexes delivered topically. J Vet Intern Med 2019;33:838-45. [PMID: 30770582 DOI: 10.1111/jvim.15426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 D’souza MJ, Gala RP, Ubale RV, D’souza B, Vo TP, Parenky AC, Mulla NS, D’sa S, D’souza M, Braz-gomes K, D’souza N, Chiriva-internati M, Zughaier S. Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. Elsevier; 2015. pp. 89-122. [DOI: 10.1016/b978-0-12-416603-5.00005-5] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. J Invest Dermatol 2015;135:2775-84. [PMID: 26039541 DOI: 10.1038/jid.2015.204] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
16 Bell J, McFadden G. Viruses for tumor therapy. Cell Host Microbe 2014;15:260-5. [PMID: 24629333 DOI: 10.1016/j.chom.2014.01.002] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 11.9] [Reference Citation Analysis]
17 Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 2016;14:168. [PMID: 27776519 DOI: 10.1186/s12916-016-0705-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 11.7] [Reference Citation Analysis]
18 Khandelwal N, Breinig M, Speck T, Michels T, Kreutzer C, Sorrentino A, Sharma AK, Umansky L, Conrad H, Poschke I, Offringa R, König R, Bernhard H, Machlenkin A, Boutros M, Beckhove P. A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. EMBO Mol Med 2015;7:450-63. [PMID: 25691366 DOI: 10.15252/emmm.201404414] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
19 Hu HJ, Liang X, Li HL, Wang HY, Gu JF, Sun LY, Xiao J, Hu JQ, Ni AM, Liu XY. Optimization of the Administration Strategy for the Armed Oncolytic Adenovirus ZD55-IL-24 in Both Immunocompromised and Immunocompetent Mouse Models. Hum Gene Ther 2021. [PMID: 34155929 DOI: 10.1089/hum.2021.036] [Reference Citation Analysis]
20 Jimenez-luna C, Prados J, Ortiz R, Melguizo C, Torres C, Caba O. Current Status of Immunotherapy Treatments for Pancreatic Cancer. Journal of Clinical Gastroenterology 2016;50:836-48. [DOI: 10.1097/mcg.0000000000000623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
21 Cekic C, Day YJ, Sag D, Linden J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 2014;74:7250-9. [PMID: 25377469 DOI: 10.1158/0008-5472.CAN-13-3583] [Cited by in Crossref: 131] [Cited by in F6Publishing: 90] [Article Influence: 16.4] [Reference Citation Analysis]
22 Cekic C, Linden J. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res 2014;74:7239-49. [PMID: 25341542 DOI: 10.1158/0008-5472.CAN-13-3581] [Cited by in Crossref: 85] [Cited by in F6Publishing: 45] [Article Influence: 10.6] [Reference Citation Analysis]
23 Lee L, Gupta M, Sahasranaman S. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. J Clin Pharmacol 2016;56:157-69. [PMID: 26183909 DOI: 10.1002/jcph.591] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 8.4] [Reference Citation Analysis]
24 Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol 2020;6:100-7. [PMID: 31697308 DOI: 10.1001/jamaoncol.2019.3848] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
25 Mirzaei R, Sarkar S, Yong VW. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints. Trends Immunol 2017;38:104-15. [PMID: 27964820 DOI: 10.1016/j.it.2016.11.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
26 Wang B, Wu S, Zeng H, Liu Z, Dong W, He W, Chen X, Dong X, Zheng L, Lin T, Huang J. CD103 + Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder. Journal of Urology 2015;194:556-62. [DOI: 10.1016/j.juro.2015.02.2941] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 10.9] [Reference Citation Analysis]
27 Aroldi F, Zaniboni A. Immunotherapy for pancreatic cancer: Present and future. Immunotherapy. 2017;9:607-616. [PMID: 28595517 DOI: 10.2217/imt-2016-0142] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
28 Furihata K, Ishiguro Y, Yoshimura N, Ito H, Katsushima S, Kaneko E, Shimabe M, Mukai M, Watanabe R, Morishige T. A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis. Clin Pharmacol Drug Dev 2021;10:870-83. [PMID: 33512065 DOI: 10.1002/cpdd.918] [Reference Citation Analysis]
29 Warnders FJ, Waaijer SJ, Pool M, Lub-de Hooge MN, Friedrich M, Terwisscha van Scheltinga AG, Deegen P, Stienen SK, Pieslor PC, Cheung HK, Kosterink JG, de Vries EG. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM. J Nucl Med 2016;57:812-7. [PMID: 26848172 DOI: 10.2967/jnumed.115.168153] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
30 Schneble E, Clifton GT, Hale DF, Peoples GE. Peptide-Based Cancer Vaccine Strategies and Clinical Results. In: Thomas S, editor. Vaccine Design. New York: Springer; 2016. pp. 797-817. [DOI: 10.1007/978-1-4939-3387-7_46] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
31 Krishnadas DK, Bai F, Lucas KG. Cancer testis antigen and immunotherapy. Immunotargets Ther 2013;2:11-9. [PMID: 27471684 DOI: 10.2147/ITT.S35570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
32 Wages NA, Slingluff CL Jr, Petroni GR. A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. Contemp Clin Trials 2015;41:172-9. [PMID: 25638752 DOI: 10.1016/j.cct.2015.01.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]